Posted by Michael Wonder on 09 Apr 2025
Xspray Pharma re-submits its FDA application
8 April 2024 - Xspray Pharma has re-submitted its application for market approval for Dasynoc, the company's lead product candidate, an amorphous dasatinib for the treatment of leukaemia.
Xspray Pharma has submitted its response to the complete response letter that the company received from the FDA in July 2024.
